A new oral treatment for ulcerative colitis using synthetic biology.
Official title: A Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative Colitis
Funded at Rise Therapeutics, LLC · NIH-11007154 · Data updated 2026-11-12
This study is testing a new oral treatment that uses your body's natural gut bacteria to help reduce inflammation and improve symptoms for people with ulcerative colitis, aiming to offer a safer option than some current medications.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rise Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Rockville, UNITED STATES) |
| Project start | September 16, 2024 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $673,379 |
| NIH project number | 1SB1DK141356-01 |
| Project ID | NIH-11007154 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are diagnosed with ulcerative colitis or other forms of inflammatory bowel disease.
✕Less likely to help
Patients with other gastrointestinal disorders unrelated to inflammatory bowel disease may not benefit from this research.
What this research studies
This research aims to create a synthetic biology-based oral therapy that utilizes natural microbiome pathways to reduce inflammation in the gut, specifically targeting ulcerative colitis. The approach focuses on harnessing the body's own microbiome to restore the intestinal barrier and regulate immune responses, which are often disrupted in inflammatory bowel disease (IBD). By developing a treatment that is both safe and effective, the researchers hope to provide an alternative to current therapies that may have severe side effects. The project will involve testing this novel therapy in clinical settings to evaluate its efficacy in managing ulcerative colitis symptoms.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment option for patients suffering from ulcerative colitis, potentially improving their quality of life.
How similar studies have gone: While the approach of using synthetic biology in this context is relatively novel, there have been successful applications of microbiome-based therapies in other areas of medicine.
Where this research is happening
-
Rise Therapeutics, LLC
Rockville, United States Active
Researchers
- Principal investigator: Fanger, Gary — Rise Therapeutics, LLC
- Study coordinator: Fanger, Gary
Related research
Other NIH-funded projects on the same topics.
-
Oral immunotherapy using engineered bacteria to treat ulcerative colitis
A new, lab-made cellular medicine using friendly gut bacteria aims to reduce inflammation in adults with ulcerative colitis and Crohn’s disease by strengthening the intestinal barrier.
-
An Oral Treatment for Ulcerative Colitis
This project is creating a new oral medicine that uses natural gut bacteria to calm inflammation for people with inflammatory bowel disease, like ulcerative colitis.
-
Outpatient pathway for severe ulcerative colitis in the right care setting
This study tests a safe, outpatient approach using an oral therapy and remote monitoring for people with acute severe ulcerative colitis to avoid hospitalization.
-
Fh15-based therapy to calm inflammation in sepsis and ulcerative colitis
A research project tests a molecule from a parasitic organism (Fh15) to reduce harmful inflammation in adults with sepsis or ulcerative colitis.
-
IMYX-3 treatment for ulcerative colitis
A new therapy approach called IMYX-3 aims to help adults with moderate to severe ulcerative colitis who have not responded well to current treatments.
-
Autoantibodies and ulcerative colitis: how avb6 antibodies may drive disease
This NIH grant aims to understand how antibodies against a gut cell protein (αvβ6) may actively contribute to ulcerative colitis and what that means for future treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.